.. Immunophénotypage-lymphocytaire, 130 a, Analyse cytométrique, vol.130, issue.130, p.131

J. Binet and G. Hospitalier-pitié-salpêtrière, Cinq histoires de leucémie lymphoïde chronique. Hématologie (editorial), pp.2-3, 2006.

P. Triadou, Quelques éléments d'histoire de l'hématologie biologique, Annales de Biologie Clinique, 2000.

L. Morton, S. Wang, S. Devesa, P. Hartge, D. Weisenburger et al., Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001, Blood, vol.107, issue.1, pp.265-76, 1992.
DOI : 10.1182/blood-2005-06-2508

S. Wu, S. Huang, C. Lin, Y. Lin, C. Chang et al., The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect, Blood, vol.116, issue.22, pp.4430-4435, 1986.
DOI : 10.1182/blood-2010-05-285221

A. Blair, M. Purdue, D. Weisenburger, and D. Baris, Chemical exposures and risk of chronic lymphocytic leukaemia, British Journal of Haematology, vol.12, issue.1, pp.753-61, 2007.
DOI : 10.1097/00043764-200205000-00015

E. Tegg, R. Thomson, J. Stankovich, A. Banks, C. Flowers et al., Evidence for a common genetic aetiology in high-risk families with multiple haematological malignancy subtypes, British Journal of Haematology, vol.109, issue.4, pp.456-62, 2010.
DOI : 10.1111/j.1365-2141.2010.08267.x

L. Goldin and S. Slager, Familial CLL: Genes and Environment. ASH Education Program Book, pp.339-345, 2007.
DOI : 10.1182/asheducation-2007.1.339

URL : http://asheducationbook.hematologylibrary.org/content/2007/1/339.full.pdf

A. Raval, S. Tanner, J. Byrd, E. Angerman, J. Perko et al., Downregulation of deathassociated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell, pp.879-90, 2007.

D. Bernardo, M. Crowther-swanepoel, D. Broderick, P. Webb, E. Sellick et al., A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia, Nature Genetics, vol.108, issue.10, pp.1204-1214, 2008.
DOI : 10.1002/sim.4780040112

K. Foon and M. Hallek, Changing paradigms in the treatment of chronic lymphocytic leukemia. Leukemia. 2010 mars, pp.500-511

R. Thomas, I. Ribeiro, P. Shepherd, P. Johnson, M. Cook et al., Spontaneous clinical regression in chronic lymphocytic leukaemia, British Journal of Haematology, vol.7, issue.2, pp.341-346, 2002.
DOI : 10.1007/s002770050113

M. Hallek, B. Cheson, D. Catovsky, F. Caligaris-cappio, G. Dighiero et al., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood, vol.111, issue.12, pp.5446-5456, 2008.
DOI : 10.1182/blood-2007-06-093906

P. Johansson, L. Eisele, L. Klein-hitpass, L. Sellmann, U. Dührsen et al., Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia, Leukemia Research, vol.34, issue.7, pp.892-900, 2010.
DOI : 10.1016/j.leukres.2010.02.038

G. Nowakowski, J. Hoyer, T. Shanafelt, C. Zent, T. Call et al., Percentage of Smudge Cells on Routine Blood Smear Predicts Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.27, issue.11, pp.1844-1849, 2009.
DOI : 10.1200/JCO.2008.17.0795

A. O. Landgren, B-Cell Clones as Early Markers for Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.360, issue.7, pp.659-67, 2009.
DOI : 10.1056/NEJMoa0806122

E. Matutes, K. Owusu-ankomah, R. Morilla, G. Marco, J. Houlihan et al., The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL, Leukemia, vol.8, issue.10, pp.1640-1645, 1994.

E. Moreau, E. Matutes, A. Hern, R. Morilla, A. Morilla et al., Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b) American journal of clinical pathology, pp.378-82

G. Delespesse, U. Suter, D. Mossalayi, B. Bettler, M. Sarfati et al., Expression, Structure, and Function of the CD23 Antigen Advances in Immunology [Internet] Academic Press, pp.149-91, 1991.

L. Nitschke, The role of CD22 and other inhibitory co-receptors in B-cell activation, Current Opinion in Immunology, vol.17, issue.3, pp.290-297, 2005.
DOI : 10.1016/j.coi.2005.03.005

L. Ginaldi, D. Martinis, M. Matutes, E. Farahat, N. Morilla et al., Levels of expression of CD19 and CD20 in chronic B cell leukaemias, Journal of Clinical Pathology, vol.51, issue.5, pp.364-373, 1998.
DOI : 10.1136/jcp.51.5.364

J. Delgado, E. Matutes, A. Morilla, R. Morilla, K. Owusu-ankomah et al., Diagnostic Significance of CD20 and FMC7 Expression in B-Cell Disorders. AJCP, pp.754-763, 2003.

J. Deans and M. Polyak, FMC7 is an epitope of CD20, Blood, vol.111, issue.4, pp.2492-2492, 2008.
DOI : 10.1182/blood-2007-11-126243

N. Almasri, R. Duque, J. Iturraspe, E. Everett, and R. Braylan, Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia, American Journal of Hematology, vol.40, issue.4, pp.259-63, 1992.
DOI : 10.1212/WNL.40.7.1120

P. Beum, A. Kennedy, M. Williams, M. Lindorfer, and R. Taylor, The Shaving Reaction: Rituximab/CD20 Complexes Are Removed from Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Cells by THP-1 Monocytes, The Journal of Immunology, vol.176, issue.4, pp.2600-2609, 2006.
DOI : 10.4049/jimmunol.176.4.2600

C. Rozman, F. Bosch, and E. Montserrat, Chronic lymphocytic leukemia: a changing natural history?, Leukemia, vol.11, issue.6, pp.775-783, 1997.
DOI : 10.1038/sj.leu.2400679

G. Pangalis, T. Vassilakopoulos, M. Dimopoulou, M. Siakantaris, F. Kontopidou et al., B?chronic lymphocytic leukemia: practical aspects. Hematological Oncology, pp.103-149, 2002.
DOI : 10.1002/hon.696

A. Tsimberidou and M. Keating, Richter syndrome. Cancer, janv, vol.15103, issue.2, pp.216-244, 2005.

S. Rasi, V. Spina, A. Bruscaggin, T. Vaisitti, C. Tripodo et al., A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome, British Journal of Haematology, vol.60, issue.3, pp.284-94, 2011.
DOI : 10.1016/j.neuron.2008.10.006

D. Rossi, V. Spina, C. Deambrogi, S. Rasi, L. Laurenti et al., The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood, pp.3391-3401, 2011.

S. Aydin, D. Rossi, L. Bergui, D. Arena, G. Ferrero et al., CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?, Blood, vol.111, issue.12, pp.5646-5653, 2008.
DOI : 10.1182/blood-2008-01-129726

K. Hodgson, G. Ferrer, E. Montserrat, and C. Moreno, Chronic lymphocytic leukemia and autoimmunity: a systematic review, Haematologica, vol.96, issue.5, pp.752-61, 2011.
DOI : 10.3324/haematol.2010.036152

C. Moreno, K. Hodgson, G. Ferrer, M. Elena, X. Filella et al., Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance, Blood, vol.116, issue.23, pp.4771-4776, 20102.
DOI : 10.1182/blood-2010-05-286500

A. Michallet, J. Rossignol, B. Cazin, and L. Ysebaert, Rituximab???cyclophosphamide???dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.95, issue.7, pp.1401-1404, 2011.
DOI : 10.1002/ajh.20665

P. Wadhwa and V. Morrison, Infectious complications of chronic lymphocytic leukemia. Seminars in oncology, pp.240-249, 2006.

E. Morra, A. Nosari, and M. Montillo, Infectious complications in chronic lymphocytic leukaemia. Hematology and Cell Therapy, pp.145-51, 1999.

E. Anaissie, D. Kontoyiannis, O. Brien, S. Kantarjian, H. Robertson et al., Infections in Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine. Annals of Internal Medicine, pp.559-566, 1998.

M. Keating, O. Brien, S. Kantarjian, H. Plunkett, W. Estey et al., Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent, Blood, vol.81, issue.11, pp.2878-84, 1993.

S. Molica, P. Musto, F. Chiurazzi, G. Specchia, M. Brugiatelli et al., Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study, Haematologica, vol.81, issue.2, pp.121-126, 1996.

H. Chapel, M. Dicato, H. Gamm, V. Brennan, F. Ries et al., Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes, British Journal of Haematology, vol.3, issue.1, pp.209-221, 1994.
DOI : 10.1001/archinte.132.4.562

M. Sinisalo, J. Aittoniemi, H. Käyhty, and J. Vilpo, Vaccination Against Infections in Chronic Lymphocytic Leukemia, Leukemia & Lymphoma, vol.48, issue.7, pp.649-52, 2003.
DOI : 10.1046/j.1365-2249.2000.01109.x

A. Hartkamp, A. Mulder, G. Rijkers, H. Van-velzen-blad, and D. Biesma, Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia. Vaccine, pp.13-141671, 2001.

M. Sinisalo, J. Aittoniemi, P. Oivanen, H. Käyhty, R. Ölander et al., Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia, British Journal of Haematology, vol.106, issue.1, pp.107-117, 2001.
DOI : 10.1001/archinte.1960.03820040005002

V. Morrison, K. Rai, B. Peterson, J. Kolitz, L. Elias et al., Impact of Therapy With Chlorambucil, Fludarabine, or Fludarabine Plus Chlorambucil on Infections in Patients With Chronic Lymphocytic Leukemia: Intergroup Study Cancer and Leukemia Group B 9011, Journal of Clinical Oncology, vol.19, issue.16, pp.3611-3632, 2001.
DOI : 10.1200/JCO.2001.19.16.3611

O. 'brien, S. Keating, M. Mocarski, and E. , Updated Guidelines on the Management of Cytomegalovirus Reactivation in Patients with Chronic Lymphocytic Leukemia Treated with Alemtuzumab, Clinical Lymphoma and Myeloma, vol.7, issue.2, pp.125-155, 2006.
DOI : 10.3816/CLM.2006.n.049

A. Tsimberidou, S. Wen, P. Mclaughlin, O. Brien, S. Wierda et al., Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Journal of Clinical Oncology, vol.27, issue.6, pp.904-910, 2009.
DOI : 10.1200/JCO.2008.17.5398

L. Travis, R. Curtis, B. Hankey, and J. Fraumeni, Second Cancers in patients With Chronic Lymphocytic Leukemia, JNCI Journal of the National Cancer Institute, vol.84, issue.18, pp.1422-1427, 1992.
DOI : 10.1093/jnci/84.18.1422

M. G. , R. H. Jr, and F. , Subsequent cancer in patients with chronic lymphocytic leukemia--a possible immunologic mechanism, Journal of the National Cancer Institute, vol.61, issue.2, p.337

K. Rai, A. Sawitsky, E. Cronkite, A. Chanana, R. Levy et al., Advances in the Clinical Staging of Chronic Lymphocytic Leukemia, Clinical Chemistry, vol.57, issue.12, pp.219-234, 1975.
DOI : 10.1373/clinchem.2010.159004

J. Binet, . ?l, D. Catovsky, P. Chandra, G. Dighiero et al., Chronic Lymphocytic Leukaemia: Proposals for a Revised Prognostic Staging System., British Journal of Haematology, vol.65, issue.3, pp.365-372, 1981.
DOI : 10.1002/1097-0142(197808)42:2+<941::AID-CNCR2820420717>3.0.CO;2-1

E. Montserrat, A. Alcalá, R. Parody, A. Domingo, J. García?conde et al., Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine, and prednisone, Cancer, vol.2, issue.10, pp.2369-75, 1985.
DOI : 10.1016/0360-3016(79)90736-3

R. Letestu, V. Lévy, V. Eclache, F. Baran-marszak, D. Vaur et al., Prognosis of Binet stage A chronic lymphocytic leukemia patients: the strength of routine parameters, Blood, vol.116, issue.22, pp.4588-4590, 2010.
DOI : 10.1182/blood-2010-06-288274

K. Yee, O. Brien, and S. , Chronic Lymphocytic Leukemia: Diagnosis and Treatment, Mayo Clinic Proceedings, vol.81, issue.8, pp.1105-1134, 2006.
DOI : 10.4065/81.8.1105

E. Montserrat, J. Sanchez?bisono, N. Viñolas, and C. Rozman, Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance, British Journal of Haematology, vol.6, issue.3, pp.567-75, 1986.
DOI : 10.1016/0002-9343(69)90242-3

B. Messmer, D. Messmer, S. Allen, J. Kolitz, P. Kudalkar et al., In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells, Journal of Clinical Investigation, vol.115, issue.3, pp.755-64, 2005.
DOI : 10.1172/JCI23409DS1

M. Keating, S. Lerner, H. Kantarjian, E. Freireich, O. Brien et al., The serum beta2-microglobulin level is more powerful than stage in predicting response and survival in chronic lymphocytic leukemia, Blood, vol.86, issue.1, p.606, 1995.

S. Molica, D. Levato, N. Cascavilla, L. Levato, and P. Musto, Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and ??2-microglobulin in B-cell chronic lymphocytic leukemia, European Journal of Haematology, vol.92, issue.suppl 1, pp.117-139, 1999.
DOI : 10.1111/j.1600-0609.1980.tb02364.x

C. Källander, B. Simonsson, H. Hagberg, and J. Gronowitz, Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer, pp.2450-2455, 1984.

M. Hallek, I. Langenmayer, C. Nerl, W. Knauf, H. Dietzfelbinger et al., Elevated Serum Thymidine Kinase Levels Identify a Subgroup at High Risk of Disease Progression in Early, Nonsmoldering Chronic Lymphocytic Leukemia, Blood, vol.93, issue.5, pp.1732-1739, 1999.

M. Sarfati, S. Chevret, C. Chastang, G. Biron, P. Stryckmans et al., Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia, Blood, vol.88, issue.11, pp.4259-64, 1996.

J. Lesesve, A. Florence, G. Maynadie, and P. Feugier, Prognostic relevance of soluble CD23 levels in CLL, The Hematology Journal, vol.2, issue.5, pp.355-355, 2001.
DOI : 10.1038/sj.thj.6200129

R. Damle, T. Wasil, F. Fais, F. Ghiotto, A. Valetto et al., Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia, Blood, vol.94, issue.6, pp.1840-1847, 1999.

T. Hamblin, Z. Davis, A. Gardiner, D. Oscier, and F. Stevenson, Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia, Blood, vol.94, issue.6, pp.1848-1854, 1999.

S. Fält, M. Merup, G. Tobin, U. Thunberg, G. Gahrton et al., Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. Blood, juill, vol.15106, issue.2, pp.681-690, 2005.

G. Tobin, U. Thunberg, A. Johnson, I. Thörn, O. Söderberg et al., Somatically mutated Ig VH3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood, mars, vol.1599, issue.6, pp.2262-2264, 2002.

U. Klein, Y. Tu, G. Stolovitzky, M. Mattioli, G. Cattoretti et al., Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells, The Journal of Experimental Medicine, vol.94, issue.11, pp.1625-1663, 2001.
DOI : 10.1038/ng0193-88

A. Chan, M. Iwashima, C. Turck, and A. Weiss, Zap 70, Cell. nov, vol.1371, issue.4, pp.649-62, 1992.
DOI : 10.1016/B978-012324719-3/50160-6

A. Rosenwald, A. Alizadeh, G. Widhopf, R. Simon, R. Davis et al., Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia, The Journal of Experimental Medicine, vol.8, issue.11, pp.1639-1648, 2001.
DOI : 10.1006/geno.1996.0177

L. Chen, G. Widhopf, L. Huynh, L. Rassenti, K. Rai et al., Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood, pp.4609-4614, 2002.

M. Crespo, F. Bosch, N. Villamor, B. Bellosillo, D. Colomer et al., ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.348, issue.18, pp.1764-75, 2003.
DOI : 10.1056/NEJMoa023143

J. Orchard, R. Ibbotson, Z. Davis, A. Wiestner, A. Rosenwald et al., ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. The Lancet, pp.105-116, 2004.

L. Rassenti, L. Huynh, T. Toy, L. Chen, M. Keating et al., ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.351, issue.9, pp.893-901, 2004.
DOI : 10.1056/NEJMoa040857

A. Wiestner, More ZAP for chronic lymphocytic leukemia (CLL). Blood, mars, vol.1105, issue.5, pp.1839-1879, 2005.
DOI : 10.1182/blood-2004-12-4758

URL : http://www.bloodjournal.org/content/bloodjournal/105/5/1839.full.pdf

S. Deaglio, A. Capobianco, L. Bergui, J. Dürig, F. Morabito et al., CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells, Blood, vol.102, issue.6, pp.2146-2155, 2003.
DOI : 10.1182/blood-2003-03-0989

F. Lund, N. Yu, K. Kim, M. Reth, and M. Howard, Signaling through CD38 augments B cell antigen receptor (BCR) responses and is dependent on BCR expression, The Journal of Immunology, vol.157, issue.4, pp.1455-1467, 1996.

P. Deterre, The CD38 molecule, antigen and ecto-enzyme: for which function?, Hématologie, vol.6, issue.1, pp.24-33, 2000.

P. Deterre, V. Berthelier, B. Bauvoisb, A. Dalloul, F. Schuber et al., CD38 in T-and B-cell functions. Human CD38 and related molecules, pp.146-68, 2000.

D. Poeta, G. Maurillo, L. Venditti, A. Buccisano, F. Epiceno et al., Clinical significance of CD38 expression in chronic lymphocytic leukemia, Blood, vol.98, issue.9, pp.2633-2642, 2001.
DOI : 10.1182/blood.V98.9.2633

J. Dürig, M. Naschar, U. Schmücker, K. Renzing-köhler, T. Hölter et al., CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia, Leukemia, vol.16, issue.1, pp.30-35, 2002.
DOI : 10.1038/sj.leu.2402339

S. Ibrahim, M. Keating, K. Do, O. Brien, S. Huh et al., CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia, Blood, vol.98, issue.1, pp.181-186, 2001.
DOI : 10.1182/blood.V98.1.181

G. Juliusson and G. Gahrton, Chromosome aberrations in B-cell chronic lymphocytic leukemia, Cancer Genetics and Cytogenetics, vol.45, issue.2, pp.143-60, 1990.
DOI : 10.1016/0165-4608(90)90079-P

H. Döhner, S. Stilgenbauer, A. Benner, E. Leupolt, A. Kröber et al., Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.26, pp.1910-1916, 2000.
DOI : 10.1056/NEJM200012283432602

D. Leroux, C. Lefebvre, and M. Callanan, Anomalies g??n??tiques des leuc??mies lymphoides chroniques, Pathologie Biologie, vol.51, issue.6, pp.366-74
DOI : 10.1016/S0369-8114(03)00083-X

U. Klein and R. Dalla-favera, New insights into the pathogenesis of chronic lymphocytic leukemia. Seminars in Cancer Biology, pp.377-83, 2010.

E. Matutes, D. Oscier, J. Garcia?marco, J. Ellis, A. Copplestone et al., Trisomy 12 defines a group of CLL with atypical morphology: correlation between cytogenetic, clinical and laboratory features in 544 patients, British Journal of Haematology, vol.92, issue.2, pp.382-390, 1996.
DOI : 10.1046/j.1365-2141.1996.d01-1478.x

H. Döhner, S. Stilgenbauer, M. James, A. Benner, T. Weilguni et al., 11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis, Blood, vol.89, issue.7, pp.2516-2538, 1997.

H. Dohner, K. Fischer, M. Bentz, K. Hansen, A. Benner et al., p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias, Blood. mars, vol.1585, issue.6, pp.1580-1589, 1995.

D. Gonzalez, P. Martinez, R. Wade, S. Hockley, D. Oscier et al., Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial, Journal of Clinical Oncology, vol.29, issue.16, pp.2223-2232, 2011.
DOI : 10.1200/JCO.2010.32.0838

T. Zenz, B. Eichhorst, R. Busch, T. Denzel, S. Häbe et al., Mutation and Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.29, pp.4473-4482, 2010.
DOI : 10.1200/JCO.2009.27.8762

S. S. Bullinger-l, W. K. Benner-a, B. M. , and D. K. , Incidence and clinical significance of 6q deletions in B cell chronic lymphocytic leukemia, Leukemia, vol.13, issue.9, pp.1331-1335

A. Tchirkov, C. Chaleteix, C. Magnac, Y. Vasconcelos, F. Davi et al., hTERT expression and prognosis in B-chronic lymphocytic leukemia. Annals of Oncology, pp.1476-1480, 2004.

C. Koller, B. Bekele, X. Zhou, C. Park, Z. Estrov et al., Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia, Blood, vol.108, issue.3, pp.1001-1006, 2006.
DOI : 10.1182/blood-2005-05-2110

S. Molica, G. Cutrona, G. Vitelli, R. Mirabelli, M. Molica et al., Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia, Leukemia Research, vol.31, issue.11, pp.1575-1583, 2007.
DOI : 10.1016/j.leukres.2007.03.009

G. Calin, M. Ferracin, A. Cimmino, D. Leva, G. Shimizu et al., A MicroRNA Signature Associated with Prognosis and Progression in Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.353, issue.17, pp.1793-801, 2005.
DOI : 10.1056/NEJMoa050995

L. Véronèse, intérêt pronostique et mécanismes moléculaires de l'expression de MCL-1, IL-6 et VEGF dans la leucémie lymphoïde chronique [Internet]. [Clermont-Ferrand 1]: Clermont-Ferrand, 2007.

F. Geneviève, V. Delisle, M. Gardembas, C. Foussard, J. Gardais et al., Les hémopathies lymphoïdes chroniques de l'adulte: la leucémie lymphoïde chronique et la phase de dissémination des lymphomes à petites cellules, Annales de Biologie Clinique, 2001.

J. Lesesve, P. Feugier, T. Lamy, M. Béné, M. Grégoire et al., Association of B?chronic lymphocytic leukaemia and T?large granular lymphocyte leukaemia. Clinical & Laboratory Haematology, pp.121-123, 20089.

A. Viny, A. Lichtin, B. Pohlman, T. Loughran, and J. Maciejewski, Chronic B-cell dyscrasias are an important clinical feature of T-LGL leukemia, Leukemia & Lymphoma, vol.72, issue.5, pp.932-940
DOI : 10.7326/0003-4819-146-9-200705010-00009

P. H. , M. M. , T. F. , A. , and P. G. Pignon-b, Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial on 612 patients, Blood, issue.7, pp.751414-751435

G. Dighiero, K. Maloum, B. Desablens, B. Cazin, M. Navarro et al., Chlorambucil in Indolent Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.338, issue.21, pp.1506-1520, 1998.
DOI : 10.1056/NEJM199805213382104

C. Shustik, M. R. Silver, R. Sawitsky, A. Rai, K. Shapiro et al., Treatment of early chronic lymphocytic leukemia: Intermittent chlorambucil versus observation. Hematological Oncology, pp.7-12, 1988.

L. Leoni, B. Bailey, J. Reifert, H. Bendall, R. Zeller et al., Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents, Clinical Cancer Research, vol.14, issue.1, pp.309-326, 2008.
DOI : 10.1158/1078-0432.CCR-07-1061

W. Knauf, T. Lissichkov, A. Aldaoud, R. Herbrecht, and A. Liberati, Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL) : results of an international phase III study [Internet], 2007.

K. Fischer, S. Stilgenbauer, C. Schweighofer, and J. Renschler, Bendamustine in Combinaison with rituximab (BR) for patients with relapsed chronic lymphocytic leukemia (CLL): a multicentre phase II trial of the German CLL Study Group (GCLLSG) [Internet], 2007.

M. Keating, H. Kantarjian, M. Talpaz, J. Redman, C. Koller et al., Fludarabine: a new agent with major activity against chronic lymphocytic leukemia. Blood, pp.19-25, 1989.

K. Rai, B. Peterson, F. Appelbaum, J. Kolitz, L. Elias et al., Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.343, issue.24, pp.1750-1757, 2000.
DOI : 10.1056/NEJM200012143432402

M. Leporrier, S. Chevret, B. Cazin, N. Boudjerra, P. Feugier et al., Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients, Blood, vol.98, issue.8, pp.2319-2344, 2001.
DOI : 10.1182/blood.V98.8.2319

B. Eichhorst, R. Busch, G. Hopfinger, R. Pasold, M. Hensel et al., Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia, Blood, vol.107, issue.3, pp.885-891, 2006.
DOI : 10.1182/blood-2005-06-2395

O. Brien, S. Kantarjian, H. Cortes, J. Beran, M. Koller et al., Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.19, issue.5, pp.1414-1420, 2001.

Y. Mowery, J. Weinberg, M. Kennedy, K. Bond, J. Moore et al., LMP-420: a novel purine nucleoside analog with potent cytotoxic effects for CLL cells and minimal toxicity for normal hematopoietic cells, Leukemia, vol.91, issue.9, pp.1580-1587, 2010.
DOI : 10.4049/jimmunol.164.4.2200

J. Bennett, THE USE OF ???CHOP??? IN THE TREATMENT OF CLL, British Journal of Haematology, vol.73, issue.4, pp.546-546, 1990.
DOI : 10.1111/j.1365-2141.1990.tb06353.x

M. Hansen, E. Andersen, H. Birgens, B. Christensen, T. Christensen et al., CHOP Versus Chlorambucil + Prednisolone in Chronic Lymphocytic Leukemia, Leukemia & Lymphoma, vol.30, issue.sup1, pp.97-100, 1991.
DOI : 10.1111/j.1600-0609.1981.tb00485.x

M. Keating, I. Flinn, V. Jain, J. Binet, P. Hillmen et al., Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study, Blood, vol.99, issue.10, pp.3554-3561, 2002.
DOI : 10.1182/blood.V99.10.3554

O. Brien, S. Kantarjian, H. Thomas, D. Cortes, J. Giles et al., Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer, pp.2657-63, 2003.

J. Lundin, E. Kimby, M. Björkholm, P. Broliden, F. Celsing et al., Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL), Blood, vol.100, issue.3, pp.768-773, 2002.
DOI : 10.1182/blood-2002-01-0159

P. Hillmen, A. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska et al., Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.25, issue.35, pp.5616-5639, 2007.
DOI : 10.1200/JCO.2007.12.9098

D. Huhn, V. Schilling, C. Wilhelm, M. Ho, A. Hallek et al., Rituximab therapy of patients with B-cell chronic lymphocytic leukemia, Blood, vol.98, issue.5, pp.1326-1331, 2001.
DOI : 10.1182/blood.V98.5.1326

J. Byrd, K. Rai, B. Peterson, F. Appelbaum, V. Morrison et al., Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011, Blood, vol.105, issue.1, pp.49-53, 2005.
DOI : 10.1182/blood-2004-03-0796

M. Hallek, G. Fingerle-rowson, and A. Fink, First-line treatment with fludarabine (F), cyclophosphamide (C), and rituximab (R)(FCR) versus fludarabine and cyclophosphamide (FC) improves overall survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL), Blood, vol.114, p.22, 2009.

M. Keating, O. Brien, S. Albitar, M. Lerner, S. Plunkett et al., Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.23, issue.18, pp.4079-4088, 2005.
DOI : 10.1200/JCO.2005.12.051

U. Winkler, M. Jensen, O. Manzke, H. Schulz, V. Diehl et al., Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8). Blood, pp.2217-2224, 1999.

W. Wierda, T. Kipps, J. Mayer, S. Stilgenbauer, C. Williams et al., Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.28, issue.10, pp.1749-55, 2010.
DOI : 10.1200/JCO.2009.25.3187

F. Morschhauser, 884 Phase I Study of RO5072759 (GA101) in Relapsed/Refractory Chronic Lymphocytic Leukemia, 2009.

A. Salles, F. Morchhauser, and C. Thieblemont, Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated patients-first results from a phase II study in patients with relapsed/refractory indolent NHL (INHL), Haematologica, vol.95, p.229, 2010.

M. Michallet, E. Carreras, J. Cornelissen, P. Dreger, H. Einsele et al., Allotransplants and autotransplants in CLL, Bone Marrow Transplant, vol.23, issue.1, p.53, 1999.

P. Dreger, S. Stilgenbauer, A. Benner, M. Ritgen, A. Kröber et al., The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status, Blood, vol.103, issue.7, pp.2850-2858, 2004.
DOI : 10.1182/blood-2003-05-1549

A. Brion, . Mah|-[-eacute-]-|-b, B. Kolb, B. Audhuy, P. Colombat et al., Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial, Bone Marrow Transplantation, vol.112, issue.4, pp.542-550, 2011.
DOI : 10.1182/blood-2008-02-140582

URL : https://hal.archives-ouvertes.fr/inserm-00821100

M. Michallet, P. Dreger, L. Sutton, R. Brand, S. Richards et al., Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation, Blood, vol.117, issue.5, pp.1516-1537, 20112.
DOI : 10.1182/blood-2010-09-308775

S. Paneesha and D. Milligan, Stem cell transplantation for chronic lymphocytic leukaemia, British Journal of Haematology, vol.25, issue.1, pp.145-52, 2005.
DOI : 10.1038/sj.leu.2401201

M. Michallet, E. Archimbaud, G. Bandini, P. Rowlings, H. Deeg et al., HLA-Identical Sibling Bone Marrow Transplantation in Younger Patients with Chronic Lymphocytic Leukemia, Annals of Internal Medicine, vol.124, issue.3
DOI : 10.7326/0003-4819-124-3-199602010-00005

P. Dreger, R. Brand, D. Milligan, P. Corradini, J. Finke et al., Reducedintensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia, pp.1029-1062, 2005.

P. Dreger, P. Corradini, E. Kimby, M. Michallet, D. Milligan et al., Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus, Leukemia, vol.23, issue.1, pp.12-19, 2006.
DOI : 10.1200/JCO.2005.04.531

O. Brien, S. Cunningham, C. Golenkov, A. Turkina, A. Novick et al., Phase I to II Multicenter Study of Oblimersen Sodium, a Bcl-2 Antisense Oligonucleotide, in Patients With Advanced Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.23, issue.30, pp.7697-702, 2005.
DOI : 10.1200/JCO.2005.02.4364

F. Awan, A. Johnson, R. Lapalombella, W. Hu, M. Lucas et al., Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia, Leukemia & Lymphoma, vol.110, issue.1, pp.27-38, 2010.
DOI : 10.1111/j.1365-2141.2008.07548.x

C. Chen, P. Bergsagel, H. Paul, W. Xu, A. Lau et al., Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, vol.29, issue.9, pp.1175-81, 2011.
DOI : 10.1200/JCO.2010.29.8133

A. Chanan-khan, K. Miller, L. Musial, D. Lawrence, S. Padmanabhan et al., Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study, Journal of Clinical Oncology, vol.24, issue.34, pp.5343-5349, 2006.
DOI : 10.1200/JCO.2005.05.0401

X. Badoux, M. Keating, S. Wen, B. Lee, M. Sivina et al., Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood, pp.3489-98, 2011.

S. Stilgenbauer and D. Mertens, Toward chemotherapy-free treatment of CLL, Blood, vol.118, issue.13, pp.3451-3452, 2011.
DOI : 10.1182/blood-2011-08-367748

D. Porter, B. Levine, M. Kalos, A. Bagg, and C. June, Chimeric Antigen Receptor???Modified T Cells in Chronic Lymphoid Leukemia, New England Journal of Medicine, vol.365, issue.8, pp.725-758, 2011.
DOI : 10.1056/NEJMoa1103849

M. Phelps, T. Lin, A. Johnson, E. Hurh, D. Rozewski et al., Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia, Blood, vol.113, issue.12, pp.2637-2682
DOI : 10.1182/blood-2008-07-168583

D. Stephens, A. Ruppert, K. Blum, J. Jones, J. Flynn et al., Flavopiridol treatment of patients aged 70 or older with refractory or relapsed chronic lymphocytic leukemia is a feasible and active therapeutic approach, Haematologica, vol.97, issue.3, pp.423-430
DOI : 10.3324/haematol.2011.047324

T. Shanafelt, M. Drake, M. Maurer, C. Allmer, K. Rabe et al., Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood, pp.1492-1500, 2011.

J. Arlet, C. Callens, O. Hermine, L. Darnige, E. Macintyre et al., Chronic lymphocytic leukaemia responsive to vitamin D administration, British Journal of Haematology, vol.117, issue.1, pp.148-157
DOI : 10.1182/blood-2010-07-295683

S. Böttcher, M. Ritgen, K. Fischer, S. Stilgenbauer, R. Busch et al., Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial, Journal of Clinical Oncology, vol.30, issue.9, pp.980-988
DOI : 10.1200/JCO.2011.36.9348

F. Caligaris-cappio and T. Hamblin, B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather, Journal of Clinical Oncology, vol.17, issue.1, p.399, 1999.
DOI : 10.1200/JCO.1999.17.1.399

F. Caligaris?cappio, Role of the microenvironment in chronic lymphocytic leukaemia, British Journal of Haematology, vol.95, issue.3, pp.380-388, 2003.
DOI : 10.1038/sj.leu.2401602

R. Kuppers, Mechanisms of B-cell lymphoma pathogenesis, Nature Reviews Cancer, vol.2, issue.4, pp.251-62
DOI : 10.1038/nrc746

N. Chiorazzi and M. Ferrarini, : Lessons Learned from Studies of the B Cell Antigen Receptor, Annual Review of Immunology, vol.21, issue.1, pp.841-94, 2003.
DOI : 10.1146/annurev.immunol.21.120601.141018

M. Hervé, K. Xu, Y. Ng, H. Wardemann, E. Albesiano et al., Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity, Journal of Clinical Investigation, vol.115, issue.6, pp.1636-1679, 2005.
DOI : 10.1172/JCI24387DS1

E. Meffre, M. Chiorazzi, and M. Nussenzweig, Circulating Human B Cells That Express Surrogate Light Chains Display a Unique Antibody Repertoire, The Journal of Immunology, vol.167, issue.4, pp.2151-2157, 2001.
DOI : 10.4049/jimmunol.167.4.2151

C. Haslinger, N. Schweifer, S. Stilgenbauer, H. Döhner, P. Lichter et al., Mutation Status, Journal of Clinical Oncology, vol.22, issue.19, pp.3937-3986, 2004.
DOI : 10.1200/JCO.2004.12.133

N. Chiorazzi, K. Rai, and M. Ferrarini, Chronic Lymphocytic Leukemia, New England Journal of Medicine, vol.352, issue.8, pp.804-819, 2005.
DOI : 10.1056/NEJMra041720

URL : https://hal.archives-ouvertes.fr/hal-01375537

E. Albesiano, B. Messmer, R. Damle, S. Allen, K. Rai et al., Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone, Blood, vol.102, issue.9, pp.3333-3342, 2003.
DOI : 10.1182/blood-2003-05-1585

G. Packham and F. Stevenson, Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia, Immunology, vol.11, issue.4, pp.441-450, 2005.
DOI : 10.1182/blood.V97.9.2777

L. Osorio, M. Jondal, and M. Aguilar-santeliseb, Regulation of B-CLL Apoptosis Through Membrane Receptors and Bcl-2 Family Proteins, Leukemia & Lymphoma, vol.154, issue.3-4, pp.3-4247, 1998.
DOI : 10.1002/eji.1830240532

M. Hanada, D. Delia, A. Aiello, E. Stadtmauer, and J. Reed, bcl-2 gene hypomethylation and highlevel expression in B-cell chronic lymphocytic leukemia, Blood, vol.82, issue.6, pp.1820-1828, 1993.

C. Pepper, T. Hoy, and D. Bentley, Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance, British Journal of Cancer, vol.76, issue.7, pp.935-943, 1997.
DOI : 10.1038/bjc.1997.487

R. Craig, MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia, pp.444-54, 2002.

O. Moshynska, K. Sankaran, P. Pahwa, and A. Saxena, Prognostic Significance of a Short Sequence Insertion in the MCL-1 Promoter in Chronic Lymphocytic Leukemia, JNCI Journal of the National Cancer Institute, vol.266, issue.27, pp.673-82, 2004.
DOI : 10.1038/358331a0

R. Vrhovac, D. A. Tang, R. , M. J. Zittoun, R. Ajchenbaum-cymbalista et al., Prognostic Significance of the Cell Cycle Inhibitor p27Kip1 in Chronic B-Cell Lymphocytic Leukemia, Blood, vol.91, issue.12, pp.4694-4700, 1998.

L. Lagneaux, A. Delforge, C. De-bruyn, M. Bernier, and D. Bron, Adhesion to Bone Marrow Stroma Inhibits Apoptosis of Chronic Lymphocytic Leukemia Cells, Leukemia & Lymphoma, vol.152, issue.5-6, pp.5-6445, 1999.
DOI : 10.1006/cimm.1998.1360

J. Burger, M. Burger, and T. Kipps, Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells, Blood, vol.94, issue.11, pp.3658-3667, 1999.

T. Mainou-fowler, S. Miller, S. Proctor, and A. Dickinson, The levels of TNF?, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Research, pp.157-63, 2001.

H. Cantor and E. Boyse, Functional subclasses of T-lymphocytes bearing different Ly antigens. I. The generation of functionally distinct T-cell subclasses is a differentiative process independent of antigen, Journal of Experimental Medicine, vol.141, issue.6, pp.1376-89, 1975.
DOI : 10.1084/jem.141.6.1376

J. Ledbetter, R. Rouse, H. Micklem, and L. Herzenberg, T cell subsets defined by expression of Lyt-1,2,3 and Thy-1 antigens. Two-parameter immunofluorescence and cytotoxicity analysis with monoclonal antibodies modifies current views, Journal of Experimental Medicine, vol.152, issue.2, pp.280-95, 1980.
DOI : 10.1084/jem.152.2.280

K. Hayakawa, R. Hardy, M. Honda, L. Herzenberg, A. Steinberg et al., Ly-1 B cells: functionally distinct lymphocytes that secrete IgM autoantibodies., Proceedings of the National Academy of Sciences, pp.2494-2498, 1984.
DOI : 10.1073/pnas.81.8.2494

URL : http://www.pnas.org/content/81/8/2494.full.pdf

V. Manohar, E. Brown, W. Leiserson, and T. Chused, Expression of Lyt-1 by a subset of B lymphocytes, J Immunol, vol.129, issue.2, pp.532-540, 1982.

L. Boumsell, A. Bernard, V. Lepage, L. Degos, J. Lemerle et al., Some chronic lymphocytic leukemia cells bearing surface immunoglobulins share determinants with T cells, European Journal of Immunology, vol.39, issue.12, pp.900-904, 1978.
DOI : 10.1002/eji.1830081214

F. Caligaris-cappio, M. Gobbi, M. Bofill, and G. Janossy, Infrequent normal B lymphocytes express features of B-chronic lymphocytic leukemia, Journal of Experimental Medicine, vol.155, issue.2, pp.623-631, 1982.
DOI : 10.1084/jem.155.2.623

N. Jones, M. Clabby, D. Dialynas, H. Huang, L. Herzenberg et al., Isolation of complementary DNA clones encoding the human lymphocyte glycoprotein T1/Leu-1. , Published online, pp.346-355, 1986.

M. Freeman, J. Ashkenas, D. Rees, D. Kingsley, N. Copeland et al., An ancient, highly conserved family of cysteine-rich protein domains revealed by cloning type I and type II murine macrophage scavenger receptors., Proceedings of the National Academy of Sciences, vol.87, issue.22, pp.8810-8814, 1990.
DOI : 10.1073/pnas.87.22.8810

M. Mcalister, M. Brown, A. Willis, P. Rudd, D. Harvey et al., Structural analysis of the CD5 antigen. Expression, disulphide bond analysis and physical characterisation of CD5 scavenger receptor superfamily domain 1, European Journal of Biochemistry, vol.257, issue.1, pp.131-172, 1998.
DOI : 10.1046/j.1432-1327.1998.2570131.x

K. Burgess, M. Yamamoto, K. Prasad, and C. Rudd, CD5 acts as a tyrosine kinase substrate within a receptor complex comprising T-cell receptor zeta chain/CD3 and protein-tyrosine kinases p56lck and p59fyn., Proceedings of the National Academy of Sciences, vol.89, issue.19, pp.9311-9316, 1992.
DOI : 10.1073/pnas.89.19.9311

A. Davies, S. Ley, and M. Crumpton, CD5 is phosphorylated on tyrosine after stimulation of the T-cell antigen receptor complex., Proceedings of the National Academy of Sciences, vol.89, issue.14, pp.6368-72, 1992.
DOI : 10.1073/pnas.89.14.6368

H. Gary-gouy, V. Lang, S. Sarun, L. Boumsell, and G. Bismuth, In vivo association of CD5 with tyrosine-phosphorylated ZAP-70 and p21 phospho-zeta molecules in human CD3+ thymocytes. The Journal of Immunology, oct, vol.15159, issue.8, pp.3739-3747, 1997.

K. Dennehy, R. Broszeit, D. Garnett, G. Durrheim, L. Spruyt et al., Thymocyte activation induces the association of phosphatidylinositol 3-kinase and pp120 with CD5, European Journal of Immunology, vol.156, issue.3, pp.679-86, 1997.
DOI : 10.1128/MCB.15.6.3049

G. Pani, K. Fischer, I. Mlinaric-rascan, and K. Siminovitch, Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase, Journal of Experimental Medicine, vol.184, issue.3, pp.839-52, 1996.
DOI : 10.1084/jem.184.3.839

G. Sen, G. Bikah, C. Venkataraman, and S. Bondada, Negative regulation of antigen receptor-mediated signaling by constitutive asociation of CD5 with the SHP-1 protein tyrosine phosphatase in B-1 B cells, European Journal of Immunology, vol.147, issue.10, pp.3319-3347, 1999.
DOI : 10.1128/MCB.19.4.2903

J. Perez-villar, G. Whitney, M. Bowen, D. Hewgill, A. Aruffo et al., CD5 Negatively Regulates the T-Cell Antigen Receptor Signal Transduction Pathway: Involvement of SH2-Containing Phosphotyrosine Phosphatase SHP-1, Molecular and Cellular Biology, vol.19, issue.4, pp.2903-2915, 1999.
DOI : 10.1128/MCB.19.4.2903

H. Gary-gouy, P. Bruhns, C. Schmitt, A. Dalloul, M. Daëron et al., The Pseudo-immunoreceptor Tyrosine-based Activation Motif of CD5 Mediates Its Inhibitory Action on B-cell Receptor Signaling, Journal of Biological Chemistry, vol.162, issue.1, pp.548-56, 2000.
DOI : 10.1084/jem.182.2.611

P. Youinou, C. Jamin, and P. Lydyard, CD5 expression in human B-cell populations. Immunology Today, pp.312-318, 1999.

N. Solvason and J. Kearney, The human fetal omentum: a site of B cell generation, Journal of Experimental Medicine, vol.175, issue.2, pp.397-404, 1992.
DOI : 10.1084/jem.175.2.397

R. Hardy and K. Hayakawa, Development and Physiology of LY?1 B and its Human Homolog, LEU?1 B. Immunological Reviews, pp.53-80, 1986.

P. Lydyard, P. Youinou, and A. Cooke, CD5-positive B cells in rheumatoid arthritis and chronic lymphocytic leukemia, Immunology Today, vol.8, issue.2, pp.37-46, 1987.
DOI : 10.1016/0167-5699(87)90235-0

H. Donze, C. Lue, B. Julian, W. Kutteh, A. Kantele et al., Human peritoneal B-1 cells and the influence of continuous ambulatory peritoneal dialysis on peritoneal and peripheral blood mononuclear cell (PBMC) composition and immunoglobulin levels, Clinical and Experimental Immunology, vol.109, issue.2, pp.356-61, 1997.
DOI : 10.1046/j.1365-2249.1997.4541352.x

F. Erkeller-yuksel, V. Deneys, B. Yuksel, I. Hannet, F. Hulstaert et al., Age-related changes in human blood lymphocyte subpopulations, The Journal of Pediatrics, vol.120, issue.2, pp.216-238, 1992.
DOI : 10.1016/S0022-3476(05)80430-5

D. Ali, CD5: A safeguard against autoimmunity and a shield for cancer cells, Autoimmunity Reviews, vol.8, issue.4, pp.349-53, 2009.

U. Klein and R. Dalla-favera, New Insights into the Phenotype and Cell Derivation of B Cell Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, pp.31-49, 2005.
DOI : 10.1007/3-540-29933-5_3

C. Plater?zyberk, R. Maini, K. Lam, T. Kennedy, and G. Janossy, A rheumatoid arthritis b cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. Arthritis & Rheumatism, pp.971-977, 1985.

R. Hardy, K. Hayakawa, M. Shimizu, K. Yamasaki, and T. Kishimoto, Rheumatoid factor secretion from human Leu-1+ B cells. Science, pp.81-84, 1987.

K. Hippen, L. Tze, and T. Behrens, Cd5 Maintains Tolerance in Anergic B Cells, The Journal of Experimental Medicine, vol.36, issue.5, pp.883-90
DOI : 10.1111/j.1749-6632.1992.tb24661.x

B. Bröker, A. Klajman, P. Youinou, J. Jouquan, C. Worman et al., Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies, Journal of Autoimmunity, vol.1, issue.5, pp.469-81, 1988.
DOI : 10.1016/0896-8411(88)90068-6

A. Lankester, G. Van-schijndel, J. Cordell, C. Van-noesel, and R. Van-lier, CD5 is associated with the human B cell antigen receptor complex, European Journal of Immunology, vol.136, issue.4, pp.812-818, 1994.
DOI : 10.1002/eji.1830240406

G. Bikah, J. Carey, J. Ciallella, A. Tarakhovsky, and S. Bondada, CD5-Mediated Negative Regulation of Antigen Receptor-Induced Growth Signals in B-1 B Cells, Science, vol.274, issue.5294, pp.1906-1909, 1996.
DOI : 10.1126/science.274.5294.1906

T. Adachi, J. Wienands, C. Wakabayashi, H. Yakura, M. Reth et al., SHP-1 Requires Inhibitory Co-receptors to Down-modulate B Cell Antigen Receptor-mediated Phosphorylation of Cellular Substrates, Journal of Biological Chemistry, vol.16, issue.28, pp.26648-26655, 2001.
DOI : 10.1002/(SICI)1521-4141(199910)29:10<3319::AID-IMMU3319>3.0.CO;2-9

L. Nitschke and T. Tsubata, Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends in Immunology, pp.543-50, 2004.

Y. Xu, K. Harder, N. Huntington, M. Hibbs, and D. Tarlinton, Lyn Tyrosine Kinase, Immunity, vol.22, issue.1, pp.9-18, 2005.
DOI : 10.1016/j.immuni.2004.12.004

T. Kipps and D. Carson, Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases, Blood, vol.81, issue.10, p.2475, 1993.

N. Harris, E. Jaffe, H. Stein, P. Banks, J. Chan et al., A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma study group, Current Diagnostic Pathology, vol.2, issue.1, pp.1361-92, 1994.
DOI : 10.1016/S0968-6053(00)80051-4

R. Kobayashi, L. Rassenti, G. Meisenholder, D. Carson, and T. Kipps, Autoantigen inhibits apoptosis of a human B cell leukemia that produces pathogenic rheumatoid factor, J Immunol déc, vol.15151, issue.12, pp.7273-83, 1993.

A. Contri, A. Brunati, L. Trentin, A. Cabrelle, M. Miorin et al., Chronic lymphocytic leukemia B cells contain anomalous Lyn tyrosine kinase, a putative contribution to defective apoptosis, Journal of Clinical Investigation, vol.115, issue.2, pp.369-78, 2005.
DOI : 10.1172/JCI200522094

R. Castejón, J. Vargas, Y. Romero, M. Briz, R. Muñoz et al., Modulation of apoptosis by cytokines in B?cell chronic lymphocytic leukemia, Cytometry oct, vol.1538, issue.5, pp.224-254, 1999.

M. Howard, O. Garra, A. Ishida, H. , W. Malefyt et al., Biological properties of interleukin 10, Journal of Clinical Immunology, vol.25, issue.4, pp.239-286, 1992.
DOI : 10.1146/annurev.iy.06.040188.001213

H. Gary-gouy, J. Harriague, G. Bismuth, C. Platzer, C. Schmitt et al., Human CD5 Promotes B-Cell Survival Through Stimulation of Autocrine IL-10 Production. Blood, pp.4537-4580, 2002.

M. Schena, L. Larsson, D. Gottardi, G. Gaidano, M. Carlsson et al., Growth-and Differentiation-Associated Expression of Bcl-2 in B-Chronic Lymphocytic Leukemia Cells, Blood, vol.79, issue.11, pp.2981-2990, 1992.

J. Pers, C. Berthou, N. Porakishvili, M. Burdjanadze, L. Calvez et al., CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia, Leukemia, vol.16, issue.1, pp.44-52, 2002.
DOI : 10.1038/sj.leu.2402327

G. Lugassy, V. Boussiotis, R. Ruchlemer, G. Pangalis, A. Berrebi et al., Chronic Lymphocytic Leukemia in Young Adults: Report of Six Cases Under the Age of 30 Years, Leukemia & Lymphoma, vol.4, issue.sup1, pp.179-82, 1991.
DOI : 10.1016/S0022-3476(05)81658-0

E. Montserrat, F. Gomis, T. Vallespi, A. Rios, A. Romero et al., Presenting Features and Prognosis of Chronic Lymphocytic Leukemia in Younger Adults [see Comments]. Blood, pp.1545-51, 1991.

F. Leukemia and C. , Comparison of the (A, B, C) staging and the Rai's staging from a large prospective series (935 patients) Nouvelle Revue Française d'Hématologie, pp.363-370, 1988.

T. Hamblin, J. Orchard, R. Ibbotson, Z. Davis, P. Thomas et al., CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease, Blood, vol.99, issue.3, pp.1023-1032, 20022.
DOI : 10.1182/blood.V99.3.1023